Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

Methods and apparatus are disclosed for customizing an elution rate of a stent. The stent includes a hollow strut that forms the stent, the hollow strut defining a lumenal space, a drug formulation disposed within the lumenal space of the hollow strut, and at least one side port for eluting the drug formulation in vivo. When the stent is in the radially expanded configuration the hollow strut is deformable from a first configuration that has a first elution rate for the drug formulation to a second configuration that has a second elution rate for the drug formulation. The second elution rate is faster than the first elution rate. The hollow strut deforms from the first configuration to the second configuration upon application of an applied pressure above a predetermined threshold.

An embodiment in accordance with the present invention provides an apparatus and method for inserting a lens into pocket in the cornea. The apparatus includes a handle, a plunger extending movably through the lumen of the handle, and a first and a second actuators. In particular the plunger includes a distal segment which extends beyond the distal end of the handle and the first and second actuators are coupled to the plunger configured in such a way to provide different ranges of motion and synchronized movement of a bottom, middle, and top tines of the plunger for improved and safer lens insertion into the corneal pocket.

A method of manufacturing a resorbable, macroporous bioactive glass scaffold comprising approximately 15-45% CaO, 30-70% SiO.sub.2, 0-25% Na.sub.2O, 0-17% P.sub.2O.sub.5, 0-10% MgO and 0-5% CaF.sub.2 by mass percent, produced by mixing with pore forming agents and specified heat treatments.

A fusion cage has a first component that defines an outside surface that is configured to engage a vertebral endplate, and an interior surface. The fusion cage has a second component that defines first and second opposed surfaces. One of the first and second opposed surfaces can mate with the interior surface of the first component. The fusion cage can include vertical and lateral throughholes adapted to enhance fusion.

Prosthesis (1) comprising one porous mesh (2) comprising a first face and a second face opposite the first face, the prosthesis (1) comprising: —one porous strengthening means (6) which strengthens the mesh (2) and is intended to cover at least part of one of said first and second faces of the mesh (2), —fastening means for fastening the strengthening means (3) to the mesh (2), in a position fastened to the mesh (2), the strengthening means (6) covers a peripheral part (7) of one of said first and second faces of the mesh.

Embodiments described include devices and methods for forming a porous polymer material. Devices disclosed and formed using the methods described a spacer for spinal fusion, craniomaxillofacial (CMF) structures, and other structures for tissue implants.

The present disclosure describes implantable slings suitable for use in a variety of medical applications, the implantable slings include at least one a biocompatible support member having a first surface and a second surface, the first and second surfaces including a first end, a second end, and a central region positioned therebetween, a first set of fixation elements positioned on the first end of the first surface, a second set of fixation elements positioned on the second end of the first surface, and a spacer positioned on the central region of the first surface for contacting a tissue in need of support.

An intravascular cell therapy device comprises a scaffold (2, 12) that is radially adjustable between a contracted orientation suitable for transluminal delivery to a vascular locus and an expanded orientation, and a biodegradable matrix provided on at least a portion of the scaffold that is suitable for seeding with cells and degrades in a vascular environment. The scaffold is configured to have a distal piercing tip (5) when in a deployed orientation. The scaffold comprises a plurality of sidewall panels (3, 13, 14) arranged around a longitudinal axis of the scaffold, and adjustable couplings (4) between the panels configured for adjustment between an expanded configuration and a contracted orientation, and in which each sidewall panel comprises a matrix suitable for seeding with cells.

Implantable devices may include a single, first component or a plurality of components such as first and second components, the second component being flexibly coupled to the first component. A socket extends over one or more of the component(s), the socket being configured to enhance the inter-component interaction and/or including one or more exposed surface(s) configured to exhibit one or more tiers of foreign body responses within a range of possible foreign body responses.